You are here

  • Home
  • Archive
  • Volume 7, Issue 2
  • Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

Citation Tools

Article menu

Download PDFPDF

XML
Rheumatoid arthritis
Original research
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Fleischmann RM, Alvarez DF, Bock AE, et al
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293
RMD Open 2021;7:e001578. doi: 10.1136/rmdopen-2021-001578